{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Her+2+Positive+Breast+Cancer&page=5", "query": { "condition": "Her 2 Positive Breast Cancer", "page": 5 }, "page_size": 10 }, "pagination": { "page": 5, "page_size": 10, "total_count": 243, "total_pages": 25, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Her+2+Positive+Breast+Cancer&page=6&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Her+2+Positive+Breast+Cancer&page=4&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-08T21:38:44.161Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06139107", "title": "RADIANT: Pre-op Radiation With Abemaciclib and Letrozole", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Abemaciclib", "type": "DRUG" }, { "name": "Letrozole", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mridula George, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "60 Years", "maximum_age": null, "sex": "FEMALE", "summary": "60 Years and older · Female only" }, "enrollment_count": 15, "start_date": "2024-08-22", "completion_date": "2032-09-30", "has_results": false, "last_update_posted_date": "2025-11-14", "last_synced_at": "2026-10-08T21:38:44.161Z", "location_count": 4, "location_summary": "Belleville, New Jersey • Livingston, New Jersey • New Brunswick, New Jersey + 1 more", "locations": [ { "city": "Belleville", "state": "New Jersey" }, { "city": "Livingston", "state": "New Jersey" }, { "city": "New Brunswick", "state": "New Jersey" }, { "city": "Somerville", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT06139107" }, { "nct_id": "NCT05187832", "title": "A Study of AND019 in Women With ER Positive HER2 Negative Advanced or Metastatic Breast Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced or Metastatic Breast Cancer" ], "interventions": [ { "name": "AND019 PO QD", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kind Pharmaceuticals LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 61, "start_date": "2022-10-05", "completion_date": "2026-11", "has_results": false, "last_update_posted_date": "2026-02-27", "last_synced_at": "2026-10-08T21:38:44.161Z", "location_count": 1, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT05187832" }, { "nct_id": "NCT06982521", "title": "Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "PIK3CA Mutation", "HER2- Negative Breast Cancer", "Hormone Receptor Positive Tumor", "Breast Cancer", "Metastatic Breast Cancer", "Advanced Breast Cancer" ], "interventions": [ { "name": "Zovegalisib", "type": "DRUG" }, { "name": "Capivasertib", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Relay Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 540, "start_date": "2025-08-26", "completion_date": "2031-12-31", "has_results": false, "last_update_posted_date": "2026-10-05", "last_synced_at": "2026-10-08T21:38:44.161Z", "location_count": 52, "location_summary": "Gilbert, Arizona • Beverly Hills, California • Duarte, California + 42 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06982521" }, { "nct_id": "NCT00847171", "title": "Trastuzumab, Cyclophosphamide, and Vaccine Therapy in Treating Patients With High-Risk or Metastatic Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "allogeneic GM-CSF-secreting breast cancer vaccine", "type": "BIOLOGICAL" }, { "name": "trastuzumab", "type": "BIOLOGICAL" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "flow cytometry", "type": "OTHER" }, { "name": "immunoenzyme technique", "type": "OTHER" }, { "name": "immunohistochemistry staining method", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "pharmacological study", "type": "OTHER" }, { "name": "biopsy", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "OTHER", "PROCEDURE" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 20, "start_date": "2008-12", "completion_date": "2013-06", "has_results": true, "last_update_posted_date": "2018-09-26", "last_synced_at": "2026-10-08T21:38:44.161Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00847171" }, { "nct_id": "NCT01674140", "title": "S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "anastrozole", "type": "DRUG" }, { "name": "everolimus", "type": "DRUG" }, { "name": "exemestane", "type": "DRUG" }, { "name": "goserelin acetate", "type": "DRUG" }, { "name": "letrozole", "type": "DRUG" }, { "name": "leuprolide acetate", "type": "DRUG" }, { "name": "tamoxifen citrate", "type": "DRUG" }, { "name": "placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1939, "start_date": "2013-09-12", "completion_date": "2030-01", "has_results": true, "last_update_posted_date": "2026-02-10", "last_synced_at": "2026-10-08T21:38:44.161Z", "location_count": 1455, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 887 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT01674140" }, { "nct_id": "NCT04872166", "title": "A Study of BTX-A51 in People With Advanced Solid Tumor and Breast Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumor", "Metastatic Breast Cancer" ], "interventions": [ { "name": "BTX-A51", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Edgewood Oncology Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 112, "start_date": "2021-06-07", "completion_date": "2027-05", "has_results": false, "last_update_posted_date": "2025-01-30", "last_synced_at": "2026-10-08T21:38:44.161Z", "location_count": 6, "location_summary": "Lake Mary, Florida • Sarasota, Florida • Cincinnati, Ohio + 2 more", "locations": [ { "city": "Lake Mary", "state": "Florida" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Cincinnati", "state": "Ohio" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT04872166" }, { "nct_id": "NCT00657137", "title": "APRiCOT-B: Study to Evaluate Apricoxib in Combination With Lapatinib and Capecitabine in the Treatment of HER2/Neu+ Breast Cancer (TP2001-202)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "apricoxib + lapatinib + capecitabine", "type": "DRUG" }, { "name": "placebo + lapatinib + capecitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Tragara Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 12, "start_date": "2008-04", "completion_date": "2009-09", "has_results": false, "last_update_posted_date": "2012-03-15", "last_synced_at": "2026-10-08T21:38:44.161Z", "location_count": 44, "location_summary": "Tucson, Arizona • Bakersfield, California • Berkeley, California + 40 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Bakersfield", "state": "California" }, { "city": "Berkeley", "state": "California" }, { "city": "Concord", "state": "California" }, { "city": "Fullerton", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00657137" }, { "nct_id": "NCT03725436", "title": "ALRN-6924 and Paclitaxel in Treating Patients With Advanced, Metastatic, or Unresectable Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Malignant Solid Neoplasm", "Anatomic Stage III Breast Cancer AJCC v8", "Anatomic Stage IIIA Breast Cancer AJCC v8", "Anatomic Stage IIIB Breast Cancer AJCC v8", "Anatomic Stage IIIC Breast Cancer AJCC v8", "Estrogen Receptor Positive", "HER2/Neu Negative", "Metastatic Malignant Solid Neoplasm", "Prognostic Stage III Breast Cancer AJCC v8", "Prognostic Stage IIIA Breast Cancer AJCC v8", "Prognostic Stage IIIB Breast Cancer AJCC v8", "Prognostic Stage IIIC Breast Cancer AJCC v8", "Recurrent Breast Carcinoma", "TP53 wt Allele", "Unresectable Malignant Solid Neoplasm" ], "interventions": [ { "name": "MDM2/MDMX Inhibitor ALRN-6924", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 28, "start_date": "2019-01-24", "completion_date": "2026-03-11", "has_results": false, "last_update_posted_date": "2026-03-16", "last_synced_at": "2026-10-08T21:38:44.161Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03725436" }, { "nct_id": "NCT05161195", "title": "Roll-over Study to Allow Continued Access to Ribociclib", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Metastatic Breast Cancer" ], "interventions": [ { "name": "Ribociclib", "type": "DRUG" }, { "name": "Letrozole", "type": "DRUG" }, { "name": "Anastrozole", "type": "DRUG" }, { "name": "Goserelin", "type": "DRUG" }, { "name": "Tamoxifen", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 134, "start_date": "2022-07-07", "completion_date": "2030-08-14", "has_results": false, "last_update_posted_date": "2026-10-01", "last_synced_at": "2026-10-08T21:38:44.161Z", "location_count": 16, "location_summary": "Chandler, Arizona • Fayetteville, Arkansas • Beverly Hills, California + 13 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Fort Collins", "state": "Colorado" }, { "city": "Orange", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05161195" }, { "nct_id": "NCT00003440", "title": "Paclitaxel With or Without Trastuzumab in Treating Patients With or Without HER-2/Neu Breast Cancer That is Inoperable, Recurrent, or Metastatic", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HER2-negative Breast Cancer", "HER2-positive Breast Cancer", "Recurrent Breast Cancer", "Stage IIIC Breast Cancer", "Stage IV Breast Cancer" ], "interventions": [ { "name": "paclitaxel", "type": "DRUG" }, { "name": "trastuzumab", "type": "BIOLOGICAL" }, { "name": "quality-of-life assessment", "type": "PROCEDURE" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "PROCEDURE", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 580, "start_date": "1998-07", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-06-04", "last_synced_at": "2026-10-08T21:38:44.161Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003440" } ] }